Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Defender Pharmaceuticals Inc, (DPI)-386 Nasal Gel on Ocean-Going Vessels for the Prevention and Treatment of Nausea Associated With Motion Sickness

NCT03920644 is registered in ClinicalTrials.gov with Naval Aeromedical Research Unit, Dayton as lead sponsor.

NCT NCT03920644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03920644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Defender Pharmaceuticals Inc, (DPI)-386 Nasal Gel on Ocean-Going Vessels for the Prevention and Treatment of Nausea Associated With Motion Sickness
Lead sponsor
Naval Aeromedical Research Unit, Dayton
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2019
Completion date
March 31, 2021
Enrollment
320 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of nausea associated with motion sickness, treatment of nausea associated with motion sickness